A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety
Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype.
Gespeichert in:
Veröffentlicht in: | Vaccine 2015-01, Vol.33 (2), p.396-402 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Highlights • We have developed a peptide-based pan-influenza A vaccine. • This vaccine was tested in a double-blind placebo-controlled clinical trial. • Results showed a good safety and tolerability profile. • The vaccine was immunogenic in most subjects and showed an anti-viral phenotype. |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2014.06.006 |